Skip to main content

Table 3 Prevalence of polymorphisms from pre-treatment samples observed during a therapeutic efficacy study in Madagascar, stratified by eventual outcome

From: Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Madagascar, 2018

 

Overall

N = 85

ACPR

N = 65

ETF

N = 1

Recrudescence

N = 4

Reinfection

N = 14

pfk13a

n = 83

n = 65

n = 1

n = 3

n = 14

 Wild type (no mutations detected)

83 (100%)

65 (100%)

1 (100%)

3 (100%)

14 (100%)

pfmdr1 N86Y

 Successfully amplified

n = 81

n = 62

n = 1

n = 4

n = 14

 N

64 (79%)

48 (78%)

1 (100%)

3 (75%)

12 (86%)

 N/Y

2 (3%)

2 (3%)

0 (0%)

0 (0%)

0 (0%)

 Y

15 (19%)

12 (19%)

0 (0%)

1 (25%)

2 (14%)

Y184F

 Successfully amplified

n = 82

n = 63

n = 1

n = 4

n = 14

 Y

34 (41%)

23 (36%)

1 (100%)

1 (25%)

9 (64%)

 Y/F

7 (9)

6 (10%)

0 (0%)

0 (0%)

1 (7%)

 F

41 (50%)

34 (54%)

0 (0%)

3 (75%)

4 (29%)

S1034C

 Successfully amplified

n = 77

n = 59

n = 1

n = 4

n = 13

 S

77 (100%)

59 (100%)

1 (100%)

4 (100%)

13 (100%)

N1042D

 Successfully amplified

n = 77

n = 59

n = 1

n = 4

n = 13

 N

77 (100%)

59 (100%)

1 (100%)

4 (100%)

13 (100%)

D1246Y

 Successfully amplified

n = 77

n = 59

n = 1

n = 4

n = 13

 D

73 (95%)

57 (97%)

1 (100%)

3 (75%)

12 (92%)

 D/Y

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Y

4 (5%)

2 (3%)

0 (0%)

1 (25%)

1 (8%)

pfmdr1 haplotypesb

 Amplified for all 3 codons (86, 184, 1246)

n = 74

n = 56

n = 1

n = 4

n = 13

 NFD

37 (50%)

28 (50%)

1 (100%)

3 (75%)

5 (27%)

 NYD

30 (41%)

23 (41%)

0 (0%)

0 (0%)

7 (38%)

 YFD

6 (8%)

5 (9%)

0 (0%)

1 (25%)

0 (0%)

 YYD

8 (11%)

6 (11%)

0 (0%)

0 (0%)

2 (11%)

 YYY

1 (1%)

0 (0%)

0 (0%)

0 (0%)

1 (5%)

 YFY

1 (1%)

1 (1%)

0 (0%)

0 (0%)

0 (0%)

 NFY

2 (3%)

1 (1%)

0 (0%)

0 (0%)

1 (5%)

pfcrt haplotypes

 Amplified for all 5 codons (72—76)

n = 82

n = 63

n = 1

n = 4

n = 14

 CVMNK

82 (100%)

63 (100%)

1 (100%)

4 (100%)

14 (100%)

  1. ACPR adequate clinical and parasitological response, ETF early treatment failure
  2. aInvestigated SNPs: F446I, N456Y, M476I, Y493H, R539T, I543T, P553L, R561H, C580Y
  3. bmixed infections included in the numerator for each haplotype; therefore, column totals may sum to > 100%